Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) Director Bruce Polsky sold 18,252 shares of the stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $3.95, for a total transaction of $72,095.40. Following the sale, the director directly owned 158,580 shares in the company, valued at $626,391. This represents a 10.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Bruce Polsky also recently made the following trade(s):
- On Thursday, November 19th, Bruce Polsky sold 8,750 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $4.03, for a total transaction of $35,262.50.
- On Monday, November 16th, Bruce Polsky sold 14,254 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $4.27, for a total transaction of $60,864.58.
- On Tuesday, November 17th, Bruce Polsky sold 8,720 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $4.03, for a total transaction of $35,141.60.
Atea Pharmaceuticals Stock Down 1.5%
Shares of AVIR opened at $3.93 on Friday. Atea Pharmaceuticals, Inc. has a fifty-two week low of $2.92 and a fifty-two week high of $6.45. The firm’s 50 day moving average price is $4.68 and its 200 day moving average price is $4.94. The company has a market cap of $315.58 million, a P/E ratio of -2.02 and a beta of 0.76.
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.11. Research analysts forecast that Atea Pharmaceuticals, Inc. will post -1.60 earnings per share for the current year.
Hedge Funds Weigh In On Atea Pharmaceuticals
Institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in Atea Pharmaceuticals in the 2nd quarter valued at $40,548,000. Irenic Capital Management LP acquired a new stake in shares of Atea Pharmaceuticals in the 1st quarter valued at approximately $1,623,000. Hsbc Holdings PLC boosted its stake in shares of Atea Pharmaceuticals by 7.3% in the first quarter. Hsbc Holdings PLC now owns 258,989 shares of the company’s stock valued at $1,380,000 after buying an additional 17,715 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Atea Pharmaceuticals in the 1st quarter valued at about $1,133,000. Finally, Wellington Management Group LLP lifted its stake in shares of Atea Pharmaceuticals by 262.7% in the second quarter. Wellington Management Group LLP now owns 206,785 shares of the company’s stock valued at $962,000 after purchasing an additional 149,776 shares during the period. 86.67% of the stock is owned by institutional investors and hedge funds.
More Atea Pharmaceuticals News
Investors following AVIR have been watching these news items:
- Positive Sentiment: Morgan Stanley increased its price target to $8 from $7. The firm kept an “equal weight” rating, so the higher target is a positive signal but not an endorsement to outperform. Article: Atea Pharmaceuticals Stock Price Expected to Rise, Morgan Stanley Analyst Says
- Negative Sentiment: Directors Bruce Polsky and Bruno Lucidi reported multiple stock sales over the week, totaling about 79,000 shares. Repeated insider selling may weigh on sentiment, although the disclosed transactions do not by themselves indicate why the directors sold. Article: Atea Pharmaceuticals Insider Buying and Selling
Analysts Set New Price Targets
A number of equities research analysts have issued reports on AVIR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research report on Thursday, October 15th. Morgan Stanley raised their price target on Atea Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Monday. Finally, Wall Street Zen raised Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Atea Pharmaceuticals presently has an average rating of “Hold” and an average target price of $8.00.
Check Out Our Latest Stock Report on AVIR
About Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.
Featured Articles
- Five stocks we like better than Atea Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
